NYSE:LLY - Eli Lilly And Co Stock Price, Price Target & More

Eli Lilly And Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly And Co announced a quarterly dividend on Monday, May 7th. Investors of record on Thursday, May 17th will be given a dividend of $0.5625 per share on Friday, June 8th. This represents a $2.25 annualized dividend and a yield of 2.59%. The ex-dividend date is Wednesday, May 16th. View Eli Lilly And Co's Dividend History.

Eli Lilly And Co (NYSE:LLY) posted its earnings results on Tuesday, April, 24th. The company reported $1.34 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.13 by $0.21. The firm had revenue of $5.70 billion for the quarter, compared to analysts' expectations of $5.51 billion. Eli Lilly And Co had a return on equity of 35.37% and a net margin of 4.82%. The firm's revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.98 earnings per share. View Eli Lilly And Co's Earnings History.

Eli Lilly And Co is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Eli Lilly And Co.

Eli Lilly And Co issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share (EPS) guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.87. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.43 billion.

19 analysts have issued 1 year price objectives for Eli Lilly And Co's stock. Their forecasts range from $78.00 to $115.00. On average, they expect Eli Lilly And Co's stock price to reach $93.9444 in the next year. View Analyst Ratings for Eli Lilly And Co.

Some companies that are related to Eli Lilly And Co include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Press coverage about LLY stock has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eli Lilly And Co earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media stories about the company an impact score of 45.75 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Eli Lilly And Co's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.06%), Franklin Resources Inc. (3.00%), Northern Trust Corp (1.04%), Massachusetts Financial Services Co. MA (0.73%), Legal & General Group Plc (0.43%) and Schroder Investment Management Group (0.43%). Company insiders that own Eli Lilly And Co stock include Alfonso G Zulueta, Christi Shaw, Daniel Skovronsky, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly And Co.

LLY stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Neuberger Berman Group LLC, Amundi Pioneer Asset Management Inc., Sei Investments Co., Northern Trust Corp, Massachusetts Financial Services Co. MA, Swiss National Bank and Eaton Vance Management. Company insiders that have sold Eli Lilly And Co company stock in the last year include Alfonso G Zulueta, Christi Shaw, Donald A Zakrowski, Enrique A Conterno, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc and Susan Mahony. View Insider Buying and Selling for Eli Lilly And Co.

LLY stock was bought by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Schroder Investment Management Group, BlackRock Inc., LSV Asset Management, Alps Advisors Inc., Mackay Shields LLC, Point72 Asset Management L.P. and Summit Trail Advisors LLC. Company insiders that have bought Eli Lilly And Co stock in the last two years include Daniel Skovronsky, Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly And Co.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LLY stock can currently be purchased for approximately $86.88.

Eli Lilly And Co has a market capitalization of $94.30 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly And Co employs 40,655 workers across the globe.

Eli Lilly And Co's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]